ProCE Banner Activity

Expert Answers to FAQs on Management of HER2-Positive Gastroesophageal Cancers

Clinical Thought

Read this focused commentary featuring expert answers to healthcare professionals’ questions on management of HER2-positive gastroesophageal cancers, from NGS testing to caring for patients experiencing treatment-related interstitial lung disease.

Released: July 02, 2024

Expiration: July 01, 2025

Share

Faculty

Jaffer Ajani

Jaffer Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Jaffer Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas